Business News • PR NewsWire • Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

Novartis breakthrough therapy LEE011 (ribociclib) plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care

EAST HANOVER, N.J., Oct. 8, 2016 /PRNewswire/ -- Results from the pivotal Phase III MONALEESA-2 study show LEE011 (ribociclib) plus letrozole significantly extended progression-free survival (PFS) compared to a standard of care, letrozole, as a first-line treatment in postmenopausal women...

View More : http://www.prnewswire.com/news-releases/novartis-breakthrough-therapy-lee011-ribociclib-plus-letrozole-demonstrates-supe...

Releted News by prnewswire

ITC Flagship Report Released Featuring DHgate.com Founder and CEO

Spin Master enthüllt, was im Ei ist: Hatchimals schlüpfen rechtzeitig für die Feiertage